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Progress in understanding biological circuits, advances in enabling technologies 
including the high-throughput platforms of genomics, proteomics, and metabolomics,  
the evolution in drug target discovery, and the development of companion diagnostics 
set the healthcare enterprise on the verge of personalized disease management.[1-3]  
This revolution in clinical care is dependent on molecular diagnostics that predict and 
prevent disease, enabling the diagnosis and treatment of individual patients and 
populations.[4-6]  Diagnostics biomarkers are quantifiable disease characteristics which 
provide information about underlying molecular processes to define disease progression 
or predict treatment response.[7]  Familiar diagnostic biomarkers include traditional 
measurements (heart rate, blood pressure), imaging techniques (chest X-ray, 
mammograms), and protein measurements (PSA, CEA).  The revolution in biology and 
high-throughput technology has provided an opportunity to develop a new generation of 
companion and complementary diagnostics, including single nucleotide polymorphism 
(SNP) analysis, genomic and proteomic profiling, epigenetic profiling and gene 
expression profiling.  In turn, these diagnostics increase disease-specific sensitivity and 
specificity contributing to the accuracy of personalized disease management.[2,3,5,6] 
This advancing wave of innovation has induced the next generation of biotechnology to 
capture the use of companion diagnostics for the application of specific therapeutic 
agents to the clinical care of individuals and populations .[8]  Yet, as pointed out in this 
issue by Milne the potential of biomarker technologies, in the form of companion and 
complementary diagnostics, to revolutionize clinical care   has not been fully realized, 
reflecting a disconnect between the emergence of discovery technologies and models 
for their validation, early adoption and application across disease populations (Milne et 
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al).[9,10]  These limiations in the validation of molecular diagnostics has raised 
considerations around approval and marketing by regulatory agencies.[4,7,11,12]  
Moreover, as highlighted in this issue by Cohen, the paucity of biomarker validation 
serves as a considerable obstacle to the adoption of companion diagnostics by 
healthcare providers and payors (Cohen).  The evolving regulatory and reimbursement 
environments, associated with the importance ofanalytic validation and clinical 
qualification, has resulted in barriers to adoption that has restricted  the full impact of 
companion diagnostics in clinical practice. 
The emergence of analytic technologies for evaluating nucleic acids and proteins, 
associated with the deconvolution of the human genome, provided the technological 
“push” to develop molecular biomarkers for disease management.[3-5,7]  Conversely, 
advances in understanding molecular mechanisms contributing to pathogenesis have 
yielded an abundance of drug targets to individualizetherapeutic care, providing the 
associated “pull” for development of companion diagnostics.[13]  At first, compnaion 
diagnostics developed in the model of classical biomarkers, as single elements related 
to the response of a patient to a specific therapeutic agent.[14]  Their clinical utility was 
enhanced by the evolution of rapid next generation nucleic acid sequencing 
technologies coupled with mutation-specific PCR supporting high-throughput analyses. 
These initial small steps have dramatically expanded to encompass systems-level 
dysregulation of complex molecular circuits contributing to pathophysiology.[13-15]  
Panels of genetic markers and their disease-specific mutations have been cataloged 
and their value in predicting responses to targeted therapeutics is being established.  
Beyond genetics, molecular assessment of transcriptomes, SNPs,  methylation, and the 
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proteome are poised to inform the best therapeutic strategies, as exemplified in this 
issue in breast cancer (XYZ).   
While companion diagnostics reflect the envisioned future for individualized therapies[1-
5,7], their potential has yet to be realized, reflecting issues of technologies, clincial 
validation, and mechanisms.[9,10,16]  Unfortuantely, technologies supporting 
companion diagnostics have not been systematically transitioned from engines of 
discovery to diagnostics platforms supporting robust assay performance consistent with 
mainstream applications in general clinical laboratories.  Similarly, as ponted out by 
both Milne and Cohen in this issue, these platforms have not undergone 
rigorousanalytic validation, providing defined value for therapeutic management of 
disease, in the form of clinical qualification (Milne, Cohen).[4,9,10,16,17]  Further, 
diagnostic analytes may be evaluated by different technologies which have not been 
cross-validated, reducing cross-platform inter-operability.[4,7,17]  Absence of assay 
performance standards with rigorous analytic validation and standardization across 
laboratories and platforms contributes to diagnostic irreproducibility.[7,13,17]  
Additionally, quantitative and qualitative relationships between analytes and therapeutic 
management do not always undergo rigorous clinical qualification, and the evidence 
linking a companion diagnsotics with clinical outcomes may not be confusing at best as 
highlighted by Cohen (Cohen)[9,10,18,19]  The clinical utility of companion diagnostics 
should be defined in appropriately powered prospective blinded and randomized clinical 
trials, and validated in follow-up trials, to provide unambiguous guidance on the utility of 
targeted therapies.[9,10] 
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Companion diagnostics influence clinical decision-making which can substantially 
impact the economics of patient care.[1,18,19]  Indeed, as highlighted in this issue, 
companion diagnostics that quantify the expression of Her2 receptors in breast cancer 
identify patients who respond to costly monoclonal antibody therapies directed to that 
target (XYZ).  The profit margins for these companion diagnostics are justified by the 
argument that they direct the application of expensive therapeutics selectively to 
patients who will benefit in an era of constrained healthcare dollars (Milne, Cohen).  
However, the emergence of companion diagnostics specifically, and molecular 
biomarkers generally, as high profit products has been one of the engines driving the 
boom in biotechnology.[8]  Their success depends on whether these products address 
robust markets and direct decisions regarding expensive, complex, or dangerous 
therapeutic interventions.[8] At stake is a $5 billion market growing at 25% annually. 
Historically, the path for developing diagnostics included obtaining approval for 
marketing of test kits by the FDA that would then be sold to local clinical 
laboratories.[4,18,19]  However, molecular diagnostics can forego FDA approval and 
achive implementation in central laboratories.[8]  Obviating the need for FDA approval 
and offering diagnostic tests from a central laboratory, , permits more rapid timelines 
and cheaper reduced costs.  However, these higher development efficiencies are 
associated with a reciprocal reduction in the pursuit of definitive studies analytically 
validating and clinically qualifying diagnostics.[7,9,10,17]  It is this paucity of clinical 
validation, which creates uncertainties in their value to healthcare economics and to 
clinical decision making for therapeutic application, which contributes to restricted 
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integration of companion diagnsotics into patient management by payors and 
practitioners, respectively.[13,16,17] 
As highlighted in this issue, companion diagnostics  offer a path from the current empiric 
model of healthcare to the development of deterministic personalized 
medicine.[1,3,5,19]  However, the integration of companion diagnostics into practice 
management paradigms will only come about with the generation of data that clearly 
demonstrates their value proposition for both healthcare economics and clinical 
practice. .[7,9,10,16]  In that regard, the development and clinical application of 
companion diagnostics should have an established basis of evidence, reflecting clinical 
trial design, analytical methodologies, and statistical rigor.  Moreover, there may be 
benefits in centralizing federal regulatory oversight of approval, marketing, and quality 
control in application, in the FDA and/or CMS.[9,11,12]  In that context, efforts should be 
focused on collaborations across public and private sectors to facilitate the discovery 
and application of companion diagnostics that will support the application of 
molecularly-targeted therapeutics to achieve a truly personalized approach to 
healthcare.[4,7,17-19] 
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